MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia
PHASE2CompletedINTERVENTIONAL
Enrollment
24
Participants
Timeline
Start Date
April 30, 2007
Primary Completion Date
March 31, 2011
Study Completion Date
March 31, 2011
Conditions
Adult Acute Lymphoblastic Leukemia in RemissionAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Myelomonocytic Leukemia (M4)Adult Erythroleukemia (M6a)Adult Pure Erythroid Leukemia (M6b)Chronic Myelomonocytic Leukemiade Novo Myelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasm, UnclassifiablePreviously Treated Myelodysplastic SyndromesRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Acute Myeloid LeukemiaRefractory AnemiaRefractory Anemia With Excess BlastsRefractory Anemia With Ringed SideroblastsRefractory Cytopenia With Multilineage DysplasiaSecondary Acute Myeloid LeukemiaSecondary Myelodysplastic SyndromesUntreated Adult Acute Lymphoblastic LeukemiaUntreated Adult Acute Myeloid Leukemia
Interventions
DRUG
entinostat
Given PO
DRUG
sargramostim
Given SC
Trial Locations (1)
21287-8936
Johns Hopkins University, Baltimore
All Listed Sponsors
lead
National Cancer Institute (NCI)
NIH
NCT00462605 - MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter